Christian Confavreux

Christian Confavreux's AcademicInfluence.com Rankings

Biology

#11941

World Rank

#15381

Historical Rank

Neuroscience

#1974

World Rank

#2030

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Christian Confavreux Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christian Confavreux's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Rate of Pregnancy-Related Relapse in Multiple Sclerosis (1998) (1286)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. (2006) (1274)
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. (1999) (1137)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012) (1044)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012) (1037)
Relapses and progression of disability in multiple sclerosis. (2000) (996)
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. (2003) (934)
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. (2011) (845)
Natural history of multiple sclerosis: a unifying concept. (2006) (791)
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. (1999) (625)
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. (2004) (530)
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. (1980) (517)
Age at disability milestones in multiple sclerosis. (2006) (461)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial (2014) (448)
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. (1997) (430)
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses (2006) (372)
The natural history of multiple sclerosis with childhood onset (2007) (369)
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force (1997) (359)
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. (2004) (302)
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum (2007) (302)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial (2014) (298)
Secondary progressive multiple sclerosis: current knowledge and future challenges (2006) (272)
EDMUS, a European database for multiple sclerosis. (1992) (264)
The incidence and significance of anti-natalizumab antibodies (2007) (260)
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study (2015) (255)
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. (2004) (243)
Health‐related quality of life in multiple sclerosis: effects of natalizumab (2007) (190)
Natural history of multiple sclerosis with childhood onset. (2007) (188)
Modafinil for fatigue in MS (2005) (185)
A Genome-Scale DNA Repair RNAi Screen Identifies SPG48 as a Novel Gene Associated with Hereditary Spastic Paraplegia (2010) (174)
Risk of cancer from azathioprine therapy in multiple sclerosis (1996) (173)
Clinical outcomes assessment in multiple sclerosis (1996) (172)
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. (2010) (160)
Aquaporin-4 antibody–negative neuromyelitis optica (2013) (149)
The clinical course of multiple sclerosis. (2014) (148)
Regional variations in the prevalence of multiple sclerosis in French farmers (2006) (141)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (139)
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years (2012) (138)
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis (2007) (127)
Geographic variations of multiple sclerosis in France. (2010) (126)
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis (2003) (124)
Natural history of multiple sclerosis: risk factors and prognostic indicators (2007) (123)
NMO-IgG and Devic's neuromyelitis optica: a French experience (2008) (120)
Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords (2010) (119)
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: Rationale, objectives and state of advancement (2009) (107)
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom (1998) (105)
Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment (2006) (105)
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? (2010) (104)
Increased risk of multiple sclerosis relapse after in vitro fertilisation (2012) (98)
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. (2011) (95)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (94)
Assessing disability progression with the Multiple Sclerosis Functional Composite (2009) (92)
Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. (2009) (92)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
[18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti‐Hu antibodies (2000) (86)
Pregnancy and multiple sclerosis: The children of PRIMS (2006) (82)
Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability (2013) (80)
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis (2012) (80)
Reliability of Longitudinal Brain Volume Loss Measurements between 2 Sites in Patients with Multiple Sclerosis: Comparison of 7 Quantification Techniques (2012) (79)
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide (2013) (79)
Teriflunomide added to interferon-&bgr; in relapsing multiple sclerosis: A randomized phase II trial (2012) (77)
Uveitis associated with multiple sclerosis (2008) (75)
Steroid hormones in multiple sclerosis (2005) (74)
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. (2005) (72)
Diffusion Tensor–MRI Evidence for Extra-Axonal Neuronal Degeneration in Caudate and Thalamic Nuclei of Patients with Multiple Sclerosis (2012) (69)
Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia (2006) (63)
Multiple sclerosis registries in Europe – results of a systematic survey (2014) (62)
The clinical epidemiology of multiple sclerosis. (2008) (61)
Progressive amusia and aprosody. (1992) (59)
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study (2015) (57)
A benign form of neuromyelitis optica: does it exist? (2011) (56)
Mutations in the Muscle Sodium Channel Gene (SCN4A) in 13 French Families with Hyperkalemic Periodic Paralysis and Paramyotonia Congenita: Phenotype to Genotype Correlations and Demonstration of the Predominance of Two Mutations (1994) (56)
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis (2010) (53)
Brain Structures Selectively Targeted by Canine Distemper Virus in a Mouse Model Infection (1993) (52)
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a (2009) (50)
The natural history of multiple sclerosis (2006) (47)
Unusual ocular motor findings in multiple sclerosis (2006) (46)
Natural history of multiple sclerosis: implications for counselling and therapy (2002) (46)
Primary and secondary progressive multiple sclerosis (2003) (46)
Mismatch negativity (MMN) in multiple sclerosis: An event-related potentials study in 46 patients (2006) (44)
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis (2010) (43)
European validation of a standardized clinical description of multiple sclerosis (2004) (43)
Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment (2006) (42)
The distribution of multiple sclerosis (2006) (42)
Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. (1993) (42)
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion (2010) (41)
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) (41)
A pyramidal approach for automatic segmentation of multiple sclerosis lesions in brain MRI. (1998) (41)
Economic Evaluation of Multiple Sclerosis in the UK, Germany and France (1998) (41)
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use (2013) (39)
Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. (1995) (39)
Tissue remodeling in periplaque regions of multiple sclerosis spinal cord lesions (2014) (39)
Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications (2010) (36)
The acute deafness of definite multiple sclerosis: BAEP patterns. (1985) (35)
Correlation of Diffusion and Metabolic Alterations in Different Clinical Forms of Multiple Sclerosis (2012) (34)
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV‐1 infected patients with tropical spastic paraparesis (1998) (33)
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis (2015) (32)
Risk of relapse after natalizumab withdrawal (2016) (31)
Implementation of an Absolute Brain $^{1}$H-MRS Quantification Method to Assess Different Tissue Alterations in Multiple Sclerosis (2012) (30)
Cerebrospinal fluid dynamics in the tardive cauda equina syndrome of ankylosing spondylitis (1991) (28)
Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. (1986) (27)
Serum GFAP levels in optic neuropathies (2012) (27)
Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis. (1987) (26)
DNA polymorphism related to HLA-DR2 Dw2 in patients with narcolepsy (2004) (26)
Silver stain after isoelectric focusing of unconcentrated cerebrospinal fluid: Visualization of total protein and direct immunofixation of immunoglobulin G (1982) (25)
[Causes of paralysis of the hypoglossal nerve. Apropos of 32 cases]. (1990) (25)
Non-specific immunosuppressants in the treatment of multiple sclerosis (2004) (24)
Congenital protein C deficiency and superior sagittal sinus thrombosis causing isolated intracranial hypertension. (1994) (23)
[The natural history of multiple sclerosis]. (2006) (22)
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis (2016) (22)
Establishment and use of multiple sclerosis registers—EDMUS (1994) (22)
Infections and the risk of relapse in multiple sclerosis. (2002) (21)
Bilateral damage to the head of the caudate nuclei (1989) (20)
A Markov model of the natural history of multiple sclerosis. (1985) (20)
The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis (2009) (20)
Course of valvular strands in patients with stroke: cooperative study with transesophageal echocardiography. (1998) (20)
Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study (S01.004) (2013) (19)
One can prevent post-partum MS relapses by exclusive breast feeding: No (2013) (19)
Unsupervised and Adaptive Segmentation of Multispectral 3D Magnetic Resonance Images of Human Brain: A Generic Approach (2001) (18)
P.O.E.M.S. syndrome with complete recovery after treatment of a solitary plasmocytoma (1991) (18)
[Oculo-palatal myoclonus and multiple sclerosis]. (1990) (17)
Multiple Sclerosis Journal (2013) (17)
[South-Eastern France, a high risk area for multiple sclerosis?]. (1987) (16)
Danazol-induced hepatocellular carcinoma. (2003) (16)
History of multiple sclerosis in 2 successive pregnancies (2016) (16)
[Intramedullary subependymoma of the cervical spinal cord. Review of the literature a propos of a case]. (1997) (16)
Aneurysmal bone cyst of the cervical spine: report of a case investigated by computed tomographic scanning and treated by a two-stage surgical procedure. (1982) (16)
Cerebral metastases as first symptom of bronchogenic carcinoma. A prospective study of 37 cases (1991) (15)
Fulminant myasthenia gravis soon after initiation of acebutolol therapy. (1990) (15)
Teriflunomide Increases the Proportion of Patients Free from Disease Activity in the TEMSO Phase III Study (PD5.007) (2012) (14)
[Association of amyotrophic lateral sclerosis and multiple sclerosis]. (1993) (14)
Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) (2013) (14)
Defining the natural history of MS: the need for complete data and rigorous definitions (2008) (14)
[Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982]. (1983) (13)
"Absolute" quantification in Magnetic Resonance Spectroscopy: validation of a clinical protocol in multiple sclerosis (2007) (13)
Intravenous immunoglobulins, pregnancy and multiple sclerosis (2004) (13)
Course of visual evoked potentials in multiple sclerosis: electroclinical correlations and pathophysiological considerations in 25 patients. (1982) (13)
Myopathic camptocormia associated with myasthenia gravis (2013) (12)
Geographical Heterogeneity of Multiple Sclerosis Prevalence in France (2016) (12)
Emerging treatments in multiple sclerosis: Azathioprine and Mof etil (1996) (12)
[Disease-modifying treatments in multiple sclerosis]. (1999) (12)
HLA-DR2 negative narcolepsy. (1987) (12)
[The Parsonage-Turner syndrome and similar diseases. 29 cases]. (1988) (12)
Cholera Toxin β Subunit Induces the Differentiation of Human Medulloblastoma Cell Line DEV in a Neuronal Pathway (1994) (11)
Clinical progression and decision making process in multiple sclerosis (1999) (11)
[Hypersensitivity to azathioprine can simulate an aggravation of myasthenia]. (1998) (11)
Magnetic resonance imaging contribution to the diagnosis of spinal cord compression by a subdural arachnoid cyst (2004) (11)
Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis (2012) (11)
[Etiology of multiple sclerosis]. (1991) (10)
Korsakoff's syndrome as the initial presentation of multiple sclerosis (1991) (10)
[Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases]. (2011) (10)
Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy (2013) (9)
Frequency of Infections during Treatment with Teriflunomide: Pooled Data from Three Placebo-Controlled Teriflunomide Studies (P01.171) (2013) (9)
[Spatial disorientation. Report of 5 cases (author's transl)]. (1981) (9)
Reply to: Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept (2006) (9)
[Can the prognosis of multiple sclerosis be predicted?]. (2000) (9)
[Multiple sclerosis and pregnancy: clinical issues]. (1999) (9)
[Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects]. (2014) (8)
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
[Plasma exchanges in severe and acute inflammatory demyelinating attacks of the central nervous system]. (2011) (8)
Chapter 16 – Treatment of the acute relapse (2006) (8)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004) (2012) (8)
Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations (2021) (8)
[Is it possible to predict the evolution of multiple sclerosis?]. (1998) (7)
Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) (2009) (7)
[Silver stain of unconcentrated cerebrospinal fluid. Preliminary results in multiple sclerosis and other neurological diseases]. (1982) (7)
[Painful sequelae of Wallenberg's syndrome]. (1992) (7)
[Bilateral deafness, an initial manifestation of meningeal carcinomatosis]. (1992) (7)
[Dementia and psychiatric disorders in Kufs disease]. (1990) (7)
Familial hypokalaemic periodic paralysis: prevention of paralytic attacks with lithium gluconate. (1991) (7)
Teriflunomide Reduces Relapse-Related Sequelae, Hospitalizations and Corticosteroid Use: A Post-Hoc Analysis of the Phase 3 TOWER Study (P07.109) (2013) (7)
[Side effects of azathioprine (Imurel). Apropos of 313 patients treated for multiple sclerosis. Review of the literature]. (1985) (7)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006) (2012) (7)
Plasma cells in cerebrospinal fluid and multiple sclerosis: diagnostic yield and clinicobiological correlations (1986) (7)
Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006) (2012) (6)
Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) (2013) (6)
[Multiple sclerosis: a degenerative disease?]. (2008) (6)
[Treatment of multiple sclerosis]. (1962) (6)
[A brachial form of motor neuropathy caused by lead poisoning]. (1998) (6)
A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis (6)
Teriflunomide added to interferon-β in relapsing multiple sclerosis (2012) (6)
Progressive amusia and aprosody (1998) (6)
[Treatment of multiple sclerosis by Azathioprine. About 77 cases studied during 10 years (author's transl)]. (1978) (6)
Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study) (2013) (6)
[Multiple and familial meningiomatosis. A syndrome bordering on Recklinghausen's neurofibromatosis]. (1977) (5)
Multiple sclerosis: a comparison of the latent periods of different populations. (1993) (5)
Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study (2013) (5)
Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED (1999) (5)
Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174) (2013) (5)
Aneurysmal Bone Cyst of the Cervical Spine (1982) (5)
[Long-lasting and isolated Uhthoff's phenomenon after effort preceding multiple sclerosis]. (2010) (5)
Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial (2008) (5)
Effect of Teriflunomide on Relapses with Sequelae and Relapse Leading to Hospitalization in a Population with Relapsing Forms of Multiple Sclerosis: Results from the TEMSO Study (S30.003) (2012) (5)
Isotonic estimation of the intensity of a nonhomogeneous Poisson process: The multiple realization setup (1993) (5)
[Cytoimmunological profile of cerebrospinal fluid in diagnosis of multiple sclerosis]. (2005) (5)
Abstracts of Papers in Related Journals (1985) (4)
Nicotine-sensitive myasthenia gravis (1995) (4)
[Devic's neuromyelitis optica and related neurological disorders]. (2010) (4)
OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS (2005) (4)
[Course of visual evoked potentials in multiple sclerosis. Electro-clinical correlations and pathophysiological considerations in 25 patients (author's transl)]. (1981) (4)
[Idiopathic cranial polyneuropathies]. (1992) (4)
[Ineffectiveness of hyperbaric oxygen therapy in multiple sclerosis. A randomized placebo-controlled double-blind study]. (1986) (4)
Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093) (2013) (4)
[Treatment of Wilson's disease with zinc. 5 cases]. (1993) (4)
[Paralysis of abdominal muscles caused by Lyme disease]. (1993) (3)
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) (2012) (3)
Defining the natural history of multiple sclerosis: the need for complete data and rigorous definitions. Answer to Dr Tremlett et al. (2008) (3)
[Paralysis of downward gaze and chronic global amnesia as a result of a bilateral thalamo-subthalamic lesion]. (1986) (3)
Long Term Immunosuppressive Treatment with Azathioprine in Multiple Sclerosis. A 10 Year Trial with 77 Patients (1980) (3)
Acute encephalopathy and idiopathic hypereosinophilic syndrome: clinical and MRI response to early steroid treatment (1997) (3)
Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098) (2013) (3)
[Etiology of multiple sclerosis]. (1991) (3)
Combination therapy in multiple sclerosis (2007) (3)
[Multiple sclerosis: spontaneous course, natural history]. (2001) (3)
[Multiple sclerosis: positive diagnosis]. (2006) (3)
[MRI in the study of multiple sclerosis]. (1997) (3)
Mathematical models and individualized outcome estimates in multiple sclerosis. (1989) (3)
Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis (2008) (2)
Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004) (2012) (2)
Simultaneous Medullar and Cutaneous Revelation of a Cutaneomeningospinal Angiomatosis (1999) (2)
An unchanging man faced with changing times. (2012) (2)
[Nicotine and worsening myasthenia]. (1997) (2)
Relationship between Timed 25-Foot Walk Walking Speed and Health-Related Quality of Life in AFFIRM and SENTINEL (P07.097) (2012) (2)
Acute acquired toxoplasmosis causing neuroptico-meningoencephalitis in an immunocompetent boy. (1985) (2)
Thalamic stroke and congenital factor V deficiency. (1991) (2)
Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111) (2013) (2)
[Anatomo-clinical study of a case of topographic confabulation (or delusion)]. (1980) (2)
[Hepatitis B vaccination and multiple sclerosis]. (2005) (2)
Nicotine-sensitive myasthenia gravis (1994) (2)
[Familial epilepsy seizure disclosing long QT syndrome]. (1996) (2)
[Isolated facial paralysis caused by intrapetrous facial neurinoma]. (1986) (2)
[Non-hemorrhagic forms of intracranial arterial aneurysms]. (1980) (2)
[Radioimmunofixation: a new technic for characterizing immunoglobulins in unconcentrated cerebrospinal fluid. Preliminary results]. (1980) (2)
[Diagnostic criteria of different clinical forms ]. (2001) (2)
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) (2012) (2)
[New therapies in multiple sclerosis]. (2012) (2)
[Multiple sclerosis. Epidemiology, diagnosis, course, prognosis]. (1993) (2)
[The genetics of narcolepsy in 1987]. (1988) (1)
Paralysie faciale isolée par neurinome facial intrapétreux (1986) (1)
[Utilization behavior during the course of progressive multifocal leukoencephalopathy]. (1983) (1)
The incidence and clinical significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis (2006) (1)
[Multiple sclerosis (MS), an inflammatory or degenerative disease?]. (2004) (1)
Predicting multiple sclerosis: a large international multicentre study (2015) (1)
Multiple Sclerosis: Stochastic Models of Prognosis (1988) (1)
[Acute inflammatory polyradiculoneuritis: Guillain-Barré syndrome. Diagnosis, development, prognosis]. (1992) (1)
Correlation of Metabolic and Diffusivity Markers in Multiple Sclerosis using MR Spectroscopic Imaging and DTI (2009) (1)
Childhood onset multiple sclerosis: the KIDMUS study in European departments of adult neurology (2005) (1)
[Multiple sclerosis. Current etiopathogenic concepts]. (1984) (1)
Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED. European Database for MUltiple Sclerosis. EVALUation of the EDMUS system. (1999) (1)
HLA in Narcolepsy in France (1988) (1)
[Hypothalamic insufficiency following irradiation. Late, subacute and curable dementia]. (1988) (1)
[Results of cerebrospinal fluid examination. Significance of results (normal, hemorrhagic, purulent, lymphocytic, inflammatory, albumin-cytologic dissociation]. (1990) (1)
[Course of obstructions of the carotid artery in the neck. 69 cases]. (1983) (1)
[Isoprinosine treatment of multiple sclerosis. 52 cases]. (1986) (1)
Correction: Correlation of Diffusion and Metabolic Alterations in Different Clinical Forms of Multiple Sclerosis (2012) (1)
Characterization of Early White Matter Damages in Multiple Sclerosis patients with a Clinically Isolated Syndrome : a Tract Based Spatial Statistics Study (2009) (1)
[Central nervous system demyelinating diseases: an overview]. (2010) (1)
Natalizumab improves health-related quality of life in patients with relapsing multiple sclerosis (2006) (1)
Complete clinical and magnetic resonance imaging response with natalizumab in multiple sclerosis (2008) (1)
Longitudinal Tract-Based Spatial Statistics Analysis Reveals Left and Right Asymmetric DTI Alterations in Relapsing Remitting Multiple Sclerosis (2010) (1)
[Ureteral and kidney pathology revealed by sciatica: 2 case reports]. (1980) (1)
Trends in European multiple sclerosis research : proceedings of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, Lyon, France, 3-5 September 1987 (1988) (1)
Onset, Course and Prognosis of Multiple Sclerosis (1986) (1)
Pain in patients with multiple sclerosis: Effects of natalizumab (2008) (1)
[Multiple sclerosis: the new frontier]. (2006) (0)
[Letter: Effectiveness of L-tryptophan on Parkinsonian tremor. Preliminary study]. (1976) (0)
Biological Effects of Natalizumab (2009) (0)
Diagnosis of Adult Onset Leukodystrophy in a Consecutive Study of 156 Patients (S60.006) (2013) (0)
The influence of pregnancy on multiple sclerosis: a European multicentric prospective study — First results (1995) (0)
[New frontiers in multiple sclerosis]. (2008) (0)
Acknowledgement to Reviewers (2009) (0)
Oral session 30 — Multiple sclerosis (6) (2005) (0)
ORIGINAL RESEARCH Diffusion Tensor-MRI Evidence for Extra-Axonal Neuronal Degeneration in Caudate and Thalamic Nuclei of Patients with Multiple Sclerosis (2012) (0)
[Contribution of nuclear magnetic resonance imaging in multiple sclerosis]. (2006) (0)
A 10-year follow-up of the European multicenter trial of interferon β1 b in secondary-progressive multiple sclerosis (2016) (0)
[Isolated late epilepsy disclosing glioblastoma and false negatives on the scanner]. (1981) (0)
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) (2013) (0)
Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis (2006) (0)
[Death or absence of the father. Its role in the genesis of psychotic process happening between 15 and 25 years]. (1976) (0)
Subject Index Vol. 4, 1985 (1985) (0)
Cerebellar damage in Multiple Sclerosis patients: a TBSS-based analysis of DTI (2013) (0)
Characterization of NMO and NMOSD Patients with a Late Onset (P02.152) (2013) (0)
[Neck pain and isolated torticollis revealing neurologic lesions]. (1989) (0)
A Benign Form of Neuromyelitis Optica (2011) (0)
[Meningeal syndrome. Diagnostic orientation and management]. (1990) (0)
[Hepatitis B vaccination and multiple sclerosis: where are we?]. (2002) (0)
[Arnold-Chiari malformation in adults. Development of diagnostic conditions since the availability of MRI]. (1993) (0)
[Long-term therapeutic trials and multiple sclerosis: a wager?]. (1983) (0)
[Conference at Salpêtrière Hospital. January 1990. Progressive motor incoordination in a man with late partial epilepsy]. (1992) (0)
Evidence of cortico-spinal tract damage related to motor dysfunction in Multiple Sclerosis (2013) (0)
Reply to Villoslada (2020) (0)
[Multiple sclerosis. Criteria of diagnosis]. (1997) (0)
[Confusional syndrome: diagnostic trends]. (1998) (0)
Prestimus: Predictive estimates in muutple sclerosis a European multicentric prospective study (1995) (0)
Assessment of disease activity in multiple sclerosis phenotypes using a combined gadolinium and iron oxide nanoparticles MR contrast (2012) (0)
Use of data fusion technique for the automated segmentation of multiple sclerosis lesions in magnetic resonance images (1998) (0)
Posterior Tibial Tendon and Spring Ligament Lesions in Rheumatoid Arthritis (2019) (0)
Re. Multiple sclerosis and progestins: A comment to POPART'MUS (2011) (0)
[Intrapetrous neurinoma of the facial nerve. Removal by the oto-neurologic route]. (1987) (0)
Comparison of spectroscopic imaging vs. localized spectroscopy to characterize clinical forms of Multiple (2009) (0)
[Sequential MRI imaging of progressive bilateral rostro-caudal medullary infarction]. (2014) (0)
[Myasthenia syndrome. Diagnostic orientation]. (1997) (0)
Contents Vol. 4, 1985 (1985) (0)
Differentiation of Pathological Processes and Clinical Forms in Multiple Sclerosis: a Tract Based Spatial Statistics Study. (2009) (0)
[Myasthenia]. (2005) (0)
[Intracranial arteriovenous angioma in adults. A review of 100 medico-surgical cases (author's transl)]. (1982) (0)
Increased Anisotropy in Subcortical Gray Matter Structures : a Neurodegeneration Marker in Multiple Sclerosis (2008) (0)
Automatic segmentation of multiple sclerosis lesions in 2D MRI data (1997) (0)
[Isolated tonic ambulatory flexion of the foot (author's transl)]. (1981) (0)
[Pseudomyasthenic pre-Basedow ophthalmoplegia]. (1990) (0)
Diffusivity changes in the cortico-spinal tract: a marker of motor dysfunction in Multiple Sclerosis (2013) (0)
[Address from the president for 2008]. (2009) (0)
Lesion Effects on Cerebellar Peduncles DTI Metrics in MS Patients (2013) (0)
[HLA and narcolepsy. Apropos of 28 cases including 2 negative HLA-DR2]. (1988) (0)
Segmentation of MS Lesions using evidence theory, Multiple Sclerosis (1997) (0)
A preliminary step towards a European standard to evaluate MS patients: The evalued study (1995) (0)
[Diagnostic and therapeutic value of Seldinger's technique angiography in 200 neurological patients (author's transl)]. (1981) (0)
The relationship between disease severity and health-related quality of life in patients with relapsing multiple sclerosis (2006) (0)
[Contribution of lumbar puncture to the diagnosis of cephalalgia]. (1982) (0)
[Multiple sclerosis. What about treatment with monoclonal antibodies?]. (2010) (0)

This paper list is powered by the following services:

Christian Confavreux's Academic­Influence.com Rankings

Why Is Christian Confavreux Influential?

Christian Confavreux's Published Works

Published Works

Christian Confavreux's AcademicInfluence.com Rankings